Malaria Vaccines Market Progress Factors, Outlook Developments, Analysis and Projections 2024 Appraised By Global Players GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.

The Global Malaria Vaccines Market is pegged to be valued at US$ 8.5 million in 2018 and is projected to expand at a CAGR of 102.8% during the forecast period (2018-2024), as highlighted in a new report published by Coherent Market Insights. Rise in demand for vaccines for important indications on the backdrop of increasing focus on biological preparations is expected to be a major factor driving growth of the global malaria vaccines market over the foreseeable future.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/37

Global Key Players:

Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.

Table of Contents
1. Research Objective and assumption
◦ Research Objectives
◦ Assumptions
◦ Abbreviations
2. Market Purview
◦ Report Description
▪ Market Definition and Scope
◦ Executive Summary
▪ Market Snippet By Vaccines Type
▪ Market Snippet By Agent
▪ Market Snippet By Distribution Channel
▪ Market Snippet By Geography
◦ Coherent Opportunity Map (COM)

Market Dynamics

The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the market for malaria vaccines market. According to World Health Organization (WHO), in 2015, approximately 292,000 children in Africa died of malaria, at very early age of 5 years. Around 306,000 fatalities associated with malaria were reported worldwide in 2015, out of which around 90% cases were reported in Africa. According to World Health Organization (WHO), first global malaria vaccines will be piloted in the regions of sub-Saharan Africa in 2018, with the funding to around US$ 15 Mn. The program is partly funded by the Bill & Melinda Gates Foundation and African Research Centers.

Major regions affected by malaria do not have an appropriate healthcare infrastructure and standard economic conditions, due to which they are unable to pay for the better treatments and drugs. Malaria is common in sub-Saharan and African region, due to poor sanitation and healthcare standards. However, the vaccine is being developed by GSK at their lab in Belgium in collaboration with Path, which is an international non-profit organization. This ensures the cost effectiveness of the vaccine though it has taken around 30 years to develop at a cost of US$ 565 Mn. The company pledges not to make a profit from sales of the vaccine and adheres to the price range of around US$ 5 per shot.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/37

Market Taxonomy
This report segments the global malaria vaccines market on the basis of vaccines type, by agent, distribution channel, and geography. On the basis of vaccines type, the malaria vaccines market is categorized into Pre-Erythrocytic Vaccine, Erythrocytic Vaccine and Multi-antigen Vaccine. On the basis of agent, the malaria vaccines market is categorized into Plasmodium Falciparum and Plasmodium Vivax. On the basis of distribution channel, the malaria vaccines market is categorized into hospital, clinics, and community centers. For comprehensive understanding of market dynamics, the global malaria vaccines market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Increasing Accessibility And Government Support To Contribute Towards The Malaria Vaccines Market Growth

The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Support from such national and global initiatives will drive malaria vaccines market growth during the forecast period.

Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.

The P. falciparum vaccines market is projected to be the growth driver with major vaccine candidates targeting this parasite. Revenues through community centers is projected to be high as demand for preventive treatment methods is high from this end-user segment.

To Get More Information about this Market: https://www.coherentmarketinsights.com/insight/talk-to-analyst/37

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.